Vitamin D screening: evidence-based criteria for primary care

The relevant question is not whether serum 25-hydroxyvitamin D can be measured—it can, and it is the accepted laboratory indicator of systemic vitamin D status—but whether finding a low value in an otherwise well patient improves outcomes enough to offset the costs, interpretive uncertainty, and treatment cascade.

For primary care, the answer is generally no. The U.S. Preventive Services Task Force concluded in 2021 that evidence was insufficient to determine the balance of benefits and harms of screening asymptomatic, nonpregnant adults. The 2024 Endocrine Society guideline went further for a defined population, recommending against routine serum 25-hydroxyvitamin D testing in generally healthy adults younger than 75 years.

That is not a declaration that vitamin D is clinically irrelevant. It is a narrower and more useful statement: a laboratory abnormality is not automatically a screening target merely because it is common, measurable, and biologically plausible.

The shift away from universal vitamin D screening in primary care

The modern vitamin D screening model was built on an intuitively attractive sequence: measure serum 25(OH)D, identify insufficiency, prescribe supplementation, and prevent fractures or other chronic disease. The weakness lies in the final step. Plausibility is not an endpoint, and an association between low vitamin D status and illness does not establish that screening and correcting the laboratory value changes the course of disease.

The USPSTF’s 2021 position is therefore best understood as an evidence-grade judgment, not as a recommendation to ignore vitamin D-related disease. An “insufficient evidence” conclusion means that the clinical balance cannot be determined with adequate confidence. It does not mean that screening has been shown to be useless, nor does it support population-wide testing by default.

The Endocrine Society’s 2024 guidance is more operational for outpatient clinicians. In generally healthy adults under 75, routine 25(OH)D testing is discouraged. The practical implication is substantial: ordering the assay should require a clinical rationale rather than a preventive-care reflex.

There are several reasons for this restraint:

• The outcome of interest is uncertain. A low concentration is not itself the endpoint that matters. The relevant endpoints are fractures, falls, osteomalacia, clinically meaningful bone disease, or another defined consequence.
• Thresholds are not universally stable. The commonly used threshold of less than 20 ng/mL, equivalent to 50 nmol/L, is frequently described as deficiency in clinical literature. Yet a universally accepted cutoff that predicts all clinically relevant outcomes across populations has not been established.
• Assay and biological variation complicate classification. A single measurement may be interpreted as a categorical diagnosis even when the boundary between normal and abnormal is not biologically sharp.
• Treatment after testing is not automatically beneficial. Supplementation may be reasonable in selected patients, but evidence that universal screening followed by treatment reduces non-skeletal chronic disease remains definitive neither in clinical logic nor in randomized outcome data.

A test with a familiar analyte and an available treatment can still lack sufficient clinical utility when the threshold, intervention, and patient-important endpoint are poorly aligned.

The phrase “vitamin D deficiency screening guidelines for adults” consequently conceals an important distinction. Guidelines do not provide one universal testing algorithm for every adult who enters primary care. They separate asymptomatic population screening from targeted assessment in patients whose presentation or comorbidities make vitamin D status clinically consequential.

When serum 25(OH)D testing has a defensible indication

Serum total 25-hydroxyvitamin D is the standard laboratory indicator used to assess systemic vitamin D status. The decision to measure it should follow the suspected clinical problem, not precede it.

Testing is more defensible when the clinician is evaluating a condition involving bone metabolism, malabsorption, or organ function, particularly when the result could alter management. The laboratory value should then be interpreted as one component of a diagnostic assessment rather than as an independent explanation for a nonspecific symptom.

Bone and mineral metabolism

A patient with suspected metabolic bone disease is not equivalent to a healthy adult requesting a preventive panel. In that setting, the 25(OH)D result may sit within a broader evaluation of skeletal health and mineral physiology. The test is potentially relevant because vitamin D status can affect calcium handling and bone mineralization, while severe deficiency may be associated with clinically significant skeletal consequences.

The laboratory result should not, however, be used as a substitute for the rest of the assessment. A low 25(OH)D concentration does not by itself establish the cause of bone pain, weakness, low bone density, or a fracture. Nor does a value above a chosen threshold exclude every clinically relevant skeletal disorder. Primary care interpretation still depends on the presentation, medication history, renal and hepatic context, calcium-related findings where appropriate, and the reason the test was ordered.

Malabsorption and altered gastrointestinal physiology

Conditions that interfere with nutrient absorption create a different pretest probability from that of the general community population. Here, the concern is not that every adult might have a low value; it is that a specific physiological process may make vitamin D status clinically relevant.

The same principle applies after interventions or diseases that materially alter gastrointestinal absorption. Testing can be rational when the result informs nutritional management or contributes to an assessment of a broader deficiency pattern. It is less rational to order the test merely because a patient has a remote gastrointestinal diagnosis without a current clinical question.

Organ dysfunction and altered metabolism

Vitamin D status may also be relevant when organ function affects vitamin D metabolism or the handling of mineral balance. The indication should remain specific: the clinician should be able to state what decision the test is intended to inform.

That requirement is not bureaucratic minimalism. It prevents a common failure mode in outpatient medicine in which a broad laboratory panel produces a marginal abnormality, the abnormality becomes the presumed cause of an unrelated symptom, and the patient enters an indefinite cycle of retesting. The cycle is especially difficult to justify when no evidence demonstrates that normalizing the number improves the endpoint that prompted the original evaluation.

Symptoms alone are not a sufficient algorithm

Fatigue, diffuse pain, low mood, and reduced exercise tolerance are common complaints with broad differentials. Their prevalence does not convert 25(OH)D testing into a universal diagnostic response. A symptom may justify assessment of vitamin D status when it appears within a coherent clinical picture involving skeletal or metabolic disease, but the symptom by itself has limited discriminatory value.

For primary care, the useful sequence is:

1. Define the clinical problem. Identify whether the concern is bone disease, malabsorption, altered organ function, or another specific indication.

2. Estimate whether the result can change management. If no plausible result would alter treatment, further testing is difficult to defend.

3. Order serum total 25(OH)D when it answers that question. The assay is a tool, not a diagnosis.

4. Interpret the result in context. Avoid treating a threshold as a complete description of the patient’s health.

5. Reassess the original endpoint. The relevant question is whether the intervention improves the clinical problem, not whether the next laboratory value looks more reassuring.

Interpreting 25-hydroxyvitamin D thresholds without false precision

The concentration of serum total 25(OH)D is commonly reported in ng/mL or nmol/L. Clinical literature often uses less than 20 ng/mL, or 50 nmol/L, as a threshold for deficiency. Severe deficiency is frequently defined as less than 10 ng/mL, or 25 nmol/L. That severe range affects approximately 6% of adults in the United States, according to the evidence summarized for this review.

These thresholds are useful descriptors, but they should not be mistaken for universally validated biological borders. The evidence does not establish one cutoff that defines clinically important deficiency across every demographic group, health outcome, and treatment context. A value near a threshold may therefore be overinterpreted if the clinician ignores the assay, the patient’s risk profile, and the clinical endpoint under consideration.

The phrase “optimal vitamin D levels for bone health” also requires restraint. A concentration associated with adequate bone physiology in one guideline framework is not necessarily an intervention target for preventing cardiovascular disease, cancer, infection, depression, or other non-skeletal outcomes. The endpoint must be specified before the result is given therapeutic meaning.

A practical interpretation framework

The distinction between a laboratory reference interval and a treatment threshold matters. Reference intervals describe distributions within a tested population; treatment thresholds are supposed to identify patients for whom intervention improves outcomes. Those are different statistical and clinical constructs. Confusing them is one reason vitamin D testing can appear more precise than the evidence allows.

Vitamin D supplementation protocols in primary care

The Institute of Medicine sets the Recommended Dietary Allowance at 600 IU per day for adults aged 19 to 70 years and 800 IU per day for adults older than 70. These reference intakes provide a nutritional framework; they are not a universal prescription for diagnostic treatment, nor do they imply that every patient requires a serum test before receiving ordinary dietary supplementation.

The 2024 Endocrine Society guideline specifically advises empiric vitamin D supplementation above daily reference intakes without prior 25(OH)D testing for certain groups. These include adults aged 75 years or older, pregnant individuals, and adults with high-risk prediabetes.

This is a point at which routine clinical language often becomes internally inconsistent. If testing were always required before supplementation, empiric treatment without a baseline level would be indefensible. The guideline’s approach demonstrates the opposite: in selected populations, the expected clinical value of supplementation can justify treatment without first creating a laboratory classification problem.

That recommendation should not be expanded indiscriminately. A guideline for a defined risk group is not a license to prescribe high-dose vitamin D to every patient who reports fatigue or requests a preventive panel. The clinician still has to distinguish nutritional supplementation from treatment of established deficiency, account for contraindications and comorbidities, and avoid implying that an intervention proven or recommended for one outcome prevents all chronic disease.

The term “supplementation” is also clinically imprecise unless the dose, duration, indication, and intended endpoint are documented. A patient receiving a reference intake for general nutrition is not being managed in the same way as a patient with severe biochemical deficiency and a bone-related disorder. These scenarios should not be merged under the single heading of vitamin D treatment.

When baseline testing is not the central decision

For adults aged 75 years or older, pregnant individuals, and adults with high-risk prediabetes, the 2024 Endocrine Society guidance supports empiric supplementation above daily reference intakes without prior 25(OH)D measurement. The clinician may still order testing when another indication exists, but the absence of a baseline result is not, by itself, a reason to withhold the guideline-supported approach.

This is a useful example of endpoint discipline. The purpose is not to manufacture a normal serum number in an otherwise healthy person. It is to apply an intervention to a population for which the guideline finds a sufficiently plausible benefit profile, without claiming more than the evidence supports.

A targeted treatment recommendation does not transform vitamin D measurement into a population-screening requirement.

Why non-skeletal claims remain the weakest part of the argument

Low vitamin D status has been associated with a wide range of chronic conditions. Such associations are often clinically interesting and methodologically insufficient. People with chronic illness may have lower vitamin D levels because of inflammation, reduced mobility, altered nutrition, organ dysfunction, medication exposure, or other features of illness. The direction of causality is therefore not resolved by observing a low concentration in a diseased population.

The unanswered question is narrower and harder: does screening asymptomatic adults, treating those with low values, and maintaining a target concentration reduce the incidence of non-skeletal chronic disease? The evidence summarized for current guidance does not provide definitive randomized trial support for universal screening and treatment as a strategy to reduce such outcomes.

This is where surrogate endpoints create confusion. An increase in serum 25(OH)D is a biochemical response. It is not automatically a reduction in fractures, falls, cardiovascular events, cancer incidence, infections, or mortality. If the trial measures only the surrogate, the clinician cannot assume that the patient-important endpoint has improved.

The same concern applies to large observational associations. A confidence interval can be narrow around an association and still leave the causal interpretation fundamentally unresolved. Statistical precision is not the same as clinical validity. A well-powered study can estimate a biased relationship with considerable accuracy.

For outpatient practice, the consequence is straightforward: do not use speculative non-skeletal benefits to justify routine testing in adults for whom guidelines recommend against it. A test should be ordered because it addresses a defined clinical decision, not because the analyte has been associated with a long list of diseases.

What this means for independent practitioners

Independent clinicians often work without the institutional laboratory pathways and specialist review that can contain low-value testing. That makes the initial decision more important. A test ordered casually does not remain casual once it produces an abnormal result. It may trigger repeat testing, additional endocrine evaluation, unnecessary high-dose supplementation, concern about toxicity, or misplaced reassurance.

A defensible practice standard is to document the indication in clinical terms:

• suspected metabolic bone disease or another defined skeletal concern;
• a condition associated with malabsorption;
• organ dysfunction affecting vitamin D metabolism or mineral balance;
• a guideline-supported risk group in which empiric supplementation is being considered;
• another specific clinical question for which the result will change management.

Documentation should also make the endpoint explicit. If the purpose is bone-health assessment, say so. If the purpose is evaluation of malabsorption, identify the relevant concern. If the patient is in a group for whom empiric supplementation is recommended without prior testing, do not create a false requirement for laboratory confirmation.

This approach is not anti-testing. It is pro-indication. It preserves the assay for patients in whom the result has a realistic chance of improving diagnostic or therapeutic decisions and avoids converting a population-level evidence gap into an individual patient’s laboratory burden.

Clinical applicability

For generally healthy, asymptomatic adults younger than 75, routine serum 25(OH)D screening should not be part of default primary care practice. The USPSTF has found insufficient evidence to determine its net benefit, and the 2024 Endocrine Society guideline recommends against routine testing in this population.

Testing is more clinically defensible when there is a specific concern involving bone metabolism, malabsorption, or organ function, and when the result is connected to an actionable decision. Serum total 25(OH)D remains the standard indicator, but its interpretation requires attention to the clinical context and the limitations of commonly used thresholds.

The evidence also supports a separation between testing and supplementation. For selected groups—including adults aged 75 years or older, pregnant individuals, and adults with high-risk prediabetes—empiric supplementation above reference intakes may be recommended without prior blood testing. That does not establish a universal treatment protocol, and it certainly does not validate indiscriminate screening.

The strict clinical conclusion is therefore modest but durable: do not screen because vitamin D is measurable, common, or biologically fashionable. Test when the patient’s presentation creates a defined indication, the result can alter management, and the endpoint is clinically meaningful rather than merely numerical.